Posts

Amyotrophic Lateral Sclerosis (ALS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy and TPP Insights Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Amyotrophic Lateral Sclerosis (ALS) Overview Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder marked by the progressive loss of upper and lower motor neurons across the motor cortex, brainstem, and spinal cord. This cellular destruction triggers spreading muscular paralysis, eventually culminating in respiratory failure. While the exact trigger remains elusive, the underlying pathology involves a complex mix of TDP-43 and SOD1 protein misfolding, glutamate excitotoxicity, neuroinflammation, and mitochondrial collapse. Around 10% of cases are ...
Post a Comment
Read more

Glioblastoma (GBM) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Glioblastoma (GBM) Emerging Therapy and TPP Insights Thelansis’s “Glioblastoma (GBM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Glioblastoma (GBM) Overview Glioblastoma is the most common primary malignant brain tumor in adults, defined strictly under the current WHO classification as an IDH-wildtype diffuse astrocytic glioma. It is characterized by microvascular proliferation, intense therapeutic resistance, and pseudopalisading necrosis. Driven by genomic alterations like EGFR amplification and TERT promoter mutations, its management is heavily influenced by MGMT promoter methylation status, which serves as a vital predictive biomarker for alkylating chemotherapy response rather than an oncogenic driver. Patients p...
Post a Comment
Read more

Fabry Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Fabry Disease Emerging Therapy and TPP Insights Thelansis’s “Fabry Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Fabry Disease Overview Fabry disease, a rare genetic metabolic storage disorder, results in the progressive failure of organs and premature death. It arises from a mutation in the galactosidase alpha gene, causing a deficiency or absence of α-galactosidase A (GALA), a lysosomal enzyme. Consequently, this deficiency impairs the breakdown of globotriaosylceramide (Gb3) and related glycosphingolipids, gradually accumulating Gb3 and glycosphingolipids within lysosomes. These accumulations are believed to have cytotoxic, proinflammatory, and profibrotic effects. Patients with late-onset Fabry disease typically manifest s...
Post a Comment
Read more

Chronic Hand Eczema (CHE) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Chronic Hand Eczema (CHE) Emerging Therapy and TPP Insights Thelansis’s “Chronic Hand Eczema (CHE) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chronic Hand Eczema (CHE) Overview Chronic Hand Eczema is a persistent inflammatory skin disorder driven by epidermal barrier dysfunction, immune dysregulation involving Th2 and Th1 pathways, and repeated exposure to irritants or contact allergens. It presents with erythema, vesicles, fissuring, hyperkeratosis, and pruritus predominantly affecting the dorsal hands and fingers, with occupational exposure frequently implicated. Diagnosis is clinical, supported by patch testing to identify contact sensitization; IGA scoring and disease duration reflect severity. Topical corticosteroids and emoll...
Post a Comment
Read more

Melanoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Melanoma Emerging Therapy and TPP Insights Thelansis’s “Melanoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Melanoma Overview Melanoma is an aggressive malignancy arising from melanocytes — pigment-producing cells residing predominantly in the skin but also in ocular and mucosal sites — representing the most lethal form of skin cancer due to its pronounced metastatic potential. Ultraviolet radiation-induced DNA damage, particularly cyclobutane pyrimidine dimer formation, drives mutagenesis in sporadic melanoma, while germline CDKN2A mutations underlie familial predisposition. Somatic driver mutations — BRAF V600 in approximately 50%, NRAS in 15-20%, and NF1 or KIT alterations in the remaining subtypes — activate MAPK...
Post a Comment
Read more

Gastric Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Gastric Cancer Emerging Therapy and TPP Insights Thelansis’s “Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Gastric Cancer Overview Gastric cancer is the fifth most common malignancy and third leading cause of cancer mortality globally, arising predominantly as adenocarcinoma from the gastric mucosa, with Helicobacter pylori infection, dietary carcinogens, tobacco, obesity, and hereditary syndromes including CDH1 germline mutations constituting principal aetiological drivers. Molecular classification encompasses EBV-positive, microsatellite instability-high, chromosomally unstable, and genomically stable subtypes, each carrying distinct therapeutic implications. HER2 amplification occurs in approximately ...
Post a Comment
Read more

Small Cell Lung Cancer (SCLC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Small Cell Lung Cancer (SCLC) Emerging Therapy and TPP Insights Thelansis’s “Small Cell Lung Cancer (SCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Small Cell Lung Cancer (SCLC) Overview Small cell lung cancer (SCLC) is an aggressive, high-grade neuroendocrine carcinoma of the lung characterised by rapid doubling time, early metastatic dissemination, and initial chemosensitivity invariably followed by acquired resistance and relapse, with tobacco smoking as the overwhelmingly dominant aetiological driver. Genomic hallmarks include near-universal biallelic inactivation of TP53 and RB1, alongside amplification of MYC family oncogenes, producing a highly proliferative tumour with limited targetable driver mutations an...
Post a Comment
Read more